Document Detail


Evaluating the health impact of a public-private partnership: to reduce rotavirus disease in Nicaragua.
MedLine Citation:
PMID:  22495114     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this article is to describe the RotaTeq(®) Nicaragua Partnership and the evaluation of the public health impact of the vaccine conducted by the partners, including the creation of a rotavirus surveillance program and a vaccine effectiveness assessment. The three main objectives of the partnership were to demonstrate that a new rotavirus vaccine could (1) be introduced rapidly in a developing country, (2) be successfully integrated into the existing vaccine delivery infrastructure, and (3) have a significant and measurable public health impact at the end of the 3-y program. The vaccine impact assessment required collaboration among partners with different areas of expertise, including the Nicaraguan Ministry of Health, Merck, local hospitals, government health clinics, laboratories, and a Technical Advisory Group. Through the partnership, RotaTeq(®) became available in a GAVI-eligible developing country, Nicaragua, in the same year it was approved in the United States. Vaccine coverage rapidly reached over > 90% of eligible Nicaraguan children. The impact assessment evaluated over 10,000 subjects and leveraged and enhanced the existing diarrheal surveillance infrastructure, ultimately providing the scientific community with some of the first real-world rotavirus vaccine effectiveness data from a developing country. The successful public-private partnership (PPP) was internationally recognized as a model for the rapid adoption of a new vaccine in a developing world setting. The model could be adapted to benefit other PPPs interested in demonstrating the impact of their own programs.
Authors:
Shazia Khawaja; Anna Cardellino; Diana Klotz; Barbara J Kuter; Mark B Feinberg; Brenda D Colatrella; T Christopher Mast
Related Documents :
22383484 - Early experience conducting school-located vaccination programs for seasonal influenza.
22312984 - Pandemic h1n1 influenza virus in chilean commercial turkeys with genetic and serologic ...
22776384 - Measles, rubella, and varicella among the crew of a cruise ship sailing from florida, u...
22276104 - Whom and where are we not vaccinating? coverage after the introduction of a new conjuga...
6229634 - Antiallergic agents. 3. n-(1h-tetrazol-5-yl)-2-pyridinecarboxamides.
20182924 - Challenge with hepatitis b vaccine in children previously vaccinated with a hepatitis b...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-04-12
Journal Detail:
Title:  Human vaccines & immunotherapeutics     Volume:  8     ISSN:  2164-554X     ISO Abbreviation:  Hum Vaccin Immunother     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-09-13     Completed Date:  2013-01-17     Revised Date:  2014-10-09    
Medline Journal Info:
Nlm Unique ID:  101572652     Medline TA:  Hum Vaccin Immunother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  777-82     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Nicaragua
Public-Private Sector Partnerships*
Rotavirus Infections / immunology,  prevention & control*
Rotavirus Vaccines / therapeutic use*
Vaccines, Attenuated / therapeutic use
Chemical
Reg. No./Substance:
0/RotaTeq; 0/Rotavirus Vaccines; 0/Vaccines, Attenuated

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The burden of hospitalizations for head and neck neoplasm in Spain (1997-2008): an epidemiologic stu...
Next Document:  Advances in vaccines against neglected tropical diseases: enhancing physical stability of a recombin...